Final Announcement: Register by 9/14 & Save up to $300!

The 7th Annual CMHC is the Premier Multidisciplinary Congress Providing the Best Cardiometabolic Science & Clinical Education

Chairpersons

George L. Bakris, MD
Christie M. Ballantyne, MD
Robert H. Eckel, MD
Jay S. Skyler, MD, MACP

Distinguished Faculty

Caroline Apovian, MD
Lawrence Appel, MD, MPH
Timothy Bailey, MD
Harold Bays, MD
Richard Bergenstal, MD
Peter Berger, MD
Deepak L. Bhatt, MD, MPH
Ron Blankstein, MD
Robert Busch, MD
Robert Chilton, DO
William Cromwell, MD
Jaime Davidson, MD
Michael Davidson, MD
Harrison Farber, MD
Sergio Fazio, MD, PhD
Keith Ferdinand, MD
Vivian Fonseca, MD
JoAnne Foody, MD
W. Timothy Garvey, MD
James Gavin III, MD, PhD
Thomas Giles, MD
Allison Goldfine, MD
Irl Hirsch, MD
Silvio Inzucchi, MD
Terry Jacobson, MD
Lee M. Kaplan, MD, PhD
Robert Kushner, MD
Peter Libby, MD
Peter McCullough, MD, MPH
Luigi Meneghini, MD
Michelle O’Donoghue, MD, MPH
Suzanne Oparil, MD
Myung Park, MD
Anne Peters, MD
Jorge Plutzky, MD
Richard Pratley, MD
Matthew Riddle, MD
Paul Ridker, MD, MPH
Matthew Roe, MD
Julio Rosenstock, MD
Lewis Rubin, MD
Francesco Rubino, MD
Donna Ryan, MD
Marc Sabatine, MD, MPH
Ernst Schaefer, MD
Benjamin Scirica, MD, MPH
Arya Sharma, MD, PhD
Domenic Sica, MD
Allan Sniderman, MD
Gregg Stone, MD
Neil Stone, MD, MACP
Addison Taylor, MD, PhD
Peter Toth, MD, PhD
Sotirios Tsimikas, MD
James A. Underberg, MD
Alan Weder, MD
William White, MD
Stephen Wiviott, MD
Carol Wysham, MD
Bernard Zinman, MD

Translating cutting-edge science into real-world practical solutions that will undoubtedly make a significant impact on your daily practice

www.cardiometabolichealth.org

This activity is jointly sponsored by HealthScience Media, Inc. (HSM), and Medical Education Resources, Inc. (MER).
Dear Colleague:

It is impossible to separate cardiovascular from metabolic disease when it comes to risk assessment, prevention, and clinical intervention. No other multidisciplinary conference addresses the breadth and depth of this paradigm like the 7th Annual Cardiometabolic Health Congress (CMHC) – imparting the scientific basis and clinical tools essential to combat cardiometabolic risk.

The CMHC is an unprecedented expert forum – imparting real-world clinical strategies to optimally manage multiple cardiometabolic risk factors including obesity, type 2 diabetes, dyslipidemia, atherosclerosis, acute coronary syndrome, thrombosis, chronic kidney disease, and related comorbidities.

By attending the CMHC, you will have the opportunity to:

• Collaborate with our expert faculty to decipher the most recent clinical data and the immediate implications for your patients and practice.
• Access evidence-based solutions for managing complex patients with multiple cardiovascular and metabolic risk factors.
• Customize your CMHC learning experience with 15 sessions and 16 complimentary symposia to choose from.
• Preview cutting-edge products and services featured in the CMHC exhibit hall.
• Earn 29.25 CME credits.

Please join us – along with 64 world-renowned expert faculty, 33 prestigious medical associations, and 1500 of your colleagues – in our mission to combat the global health crisis emanating from cardiovascular and metabolic disease.

We look forward to your participation at the 2012 CMHC in Boston!

Best regards,

George L. Bakris, MD
The University of Chicago Medicine

Christie M. Ballantyne, MD
Baylor College of Medicine

Robert H. Eckel, MD
University of Colorado Anschutz Medical Campus

Jay S. Skyler, MD, MACP
University of Miami Miller School of Medicine

“CMHC has evolved over a relatively short period to become a world-class meeting, now sufficiently established to attract the very best faculty and attendees, yet still small enough for meaningful interaction with presenters and faculty covering ‘soup to nuts’ – the spectrum of cardiometabolic issues.” – Darren McGuire, MD
Who Attends the CMHC?

2011 Attendees by Specialty

- Cardiology: 33%
- Endocrinology: 32%
- Primary Care & Internal Medicine: 32%
- Other: 3%
- Other:

2011 Attendees by Region

- New England: 24%
- South Atlantic: 15%
- West: 22%
- North Central: 16%
- Mid-Atlantic: 11%
- South Central:

Testimonials

“Most practical and up-to-date conference linking cardiovascular disease with diabetes and hyperlipidemia.”

Stephen Podolsky, MD (West Roxbury, MA)

“Excellent conference! Well organized in terms of choosing speakers and topics. Loved the case discussions. Definitely coming back next year!”

Daisy Arce, MD (McAllen, TX)

“Great clinical trial updates – a highlight every time. Better than any of the websites.”

Dorothy Gohdes, MD (Albuquerque, NM)

“The congress exceeded my expectations. Outstanding! So many take-home points that I will start applying Monday.”

Susan Perez, NP-C (Richfield, OH)

“Really excellent, knowledgeable speakers. Best single conference on cardiometabolic issues.”

Young Choi, MD (Fort Bragg, NC)

“Wonderful conference. Hit all the major points, very well organized, great speakers.”

Brian Shapiro, MD (Jacksonville, FL)

“This was a fantastic conference – very high-level science translated into practical guidance that I can directly apply to patient care! Best conference I have ever been to!”

Laura Waite, PharmD (Ocoee, FL)

“Excellent job, and I appreciate the core presentations and overall accessibility of speakers to questions. As a clinician, I found the conference much more useful than ADA because the primary focus is on clinical management.”

Wendy Hawkins, MD (Houston, TX)
Chairpersons & Faculty

George L. Bakris, MD  
Professor of Medicine  
Director, ASH Comprehensive Hypertension Center  
The University of Chicago Medicine

Christie M. Ballantyne, MD  
Professor of Medicine  
Chief, Section of Cardiovascular Research  
Chief, Section of Cardiology  
Department of Medicine, Baylor College of Medicine  
Director, Center for Cardiovascular Disease Prevention  
Baylor College of Medicine and Methodist DeBakey Heart Center

Distinguished Faculty

Caroline Apovian, MD  
Professor of Medicine  
Boston University School of Medicine  
Director, Center for Nutrition & Weight Management  
Boston Medical Center

Harold Bays, MD  
Medical Director/President  
Louisville Metabolic and Atherosclerosis Research Center, Inc.

Deepak L. Bhatt, MD, MPH  
Chief of Cardiology, VA Boston Healthcare System  
Director, Integrated Interventional CV Program  
Brigham and Women’s Hospital  
Senior Investigator, TIMI Study Group  
Professor, Harvard Medical School

Robert Chilton, DO  
Professor of Medicine  
Director, Cardiac Catheterization Lab  
University of Texas Health Science Center

Michael Davidson, MD  
Clinical Professor of Medicine  
The University of Chicago  
Prizker School of Medicine

Keith Ferdinand, MD  
Clinical Professor, Cardiology Division  
Emory University School of Medicine  
Chair, National Forum for Heart Disease & Stroke Prevention

W. Timothy Garvey, MD  
Bakerworth Professor and Chair  
Department of Nutrition Sciences  
University of Alabama at Birmingham  
GRIECC Investigator and Staff Physician  
Birmingham VA Medical Center  
Director, UAB Diabetes Research & Training Center

Allison Goldfine, MD  
Associate Professor of Medicine  
Harvard Medical School  
Head, Clinical Behavioral & Outcomes Research  
Joslin Diabetes Center

Terry Jacobson, MD  
Professor of Medicine, Emory University  
Dir, Office of Health Promotion & Disease Prevention  
Co-Director, Lipid & CV Risk Reduction Program  
Grady Health Systems

Peter Libby, MD  
Chief, Cardiovascular Medicine  
Brigham and Women’s Hospital  
Mallinckrodt Professor of Medicine  
Harvard Medical School

Lawrence Appel, MD, MPH  
Professor of Medicine, Epidemiology & Internist Health  
Director, Welch Center for Prevention, Epidemiology & Clinical Research  
Johns Hopkins Medical Institutions

Richard Bergenstal, MD  
Executive Director  
International Diabetes Center, Park Nicollet  
Clinical Professor  
Department of Medicine  
University of Minnesota

Ron Blankstein, MD  
Co-Director  
Noninvasive Cardiovascular Imaging Fellowship  
Brigham and Women’s Hospital

William Cromwell, MD  
Adjunct Associate Professor  
Hypertension and Vascular Disease Center  
Wake Forest University School of Medicine  
Chief, Lipoprotein and Metabolic Disorders Institute

Harrison Farber, MD  
Boston University School of Medicine  
Director, Pulmonary Hypertension Center  
Boston Medical Center

Vivian Fonseca, MD  
Professor of Medicine and Pharmacology  
Tufts Tuvalu Alumni Chair in Diabetes  
Chief, Section of Endocrinology  
Tufts University Health Sciences Center

James Gavin III, MD, PhD  
CEO & Chief Medical Officer  
Healing Our Village, Inc.  
Clinical Professor of Medicine  
Emory University School of Medicine

Irl Hirsch, MD  
Director, Center for Cardiovascular Disease Prevention  
Department of Medicine, Baylor College of Medicine  
Director, Cardiovascular Wellness Program  
Medical Director  
Harvard Medical School

Lee M. Kaplan, MD, PhD  
Associate Professor of Medicine  
Harvard Medical School  
Director, Obesity, Metabolism & Nutrition Institute  
Massachusetts General Hospital

Peter McCullough, MD, MPH  
Chief Academic and Scientific Officer  
St. John Providence Health System

“CMHC has become the premier U.S. conference on cardiometabolic risk due to the expansive expertise of an all-star faculty of both basic and clinical researchers.”  
– Irl Hirsch, MD
Distinguished Faculty

Michelle O’Donoghue, MD, MPH
Associate Physician, Cardiology Division Brigham and Women’s Hospital
Assistant Professor Harvard Medical School

Anne Peters, MD
Professor, Keck School of Medicine Director, Clinical Diabetes Programs University of Southern California

Matthew Riddle, MD
Professor of Medicine Oregon Health & Science University

Julio Rosenstock, MD
Clinical Professor of Medicine University of Texas Southwestern Medical Center Director, Dallas Diabetes and Endocrine Center

Donna Ryan, MD
Professor Associate Executive Director for Clinical Research Pennington Biomedical Research Center

Benjamin Scirica, MD, MPH
Attending Cardiologist Brigham and Women’s Hospital Assistant Professor of Medicine Harvard Medical School Investigator, TIMI Study Group

Allan Sniderman, MD
Professor of Cardiology Mike Rosenbloom Lab. for Cardiovascular Research McGill University Health Centre Royal Victoria Hospital

Addison Taylor, MD, PhD
Professor of Medicine Chief, Div. of Hypertension & Clinical Pharmacology Dept. of Medicine, Baylor College of Medicine Co-Director, Vascular Medicine Clinic Michael E. DeBakey VA Medical Center

James A. Underberg, MD
Clinical Assistant Professor of Medicine NYU School of Medicine NYU Center for Prevention of Cardiovascular Disease Director, Bellevue Hospital Lipid Clinic

Stephen Wiviott, MD
Assistant Professor of Medicine Harvard Medical School Investigator, TIMI Study Group Associate Physician, Cardiovascular Division Brigham and Women’s Hospital

Robert H. Eckel, MD
Professor of Medicine Division of Endocrinology, Metabolism and Diabetes Professor of Physiology and Biophysics Charles A. Boettcher II Chair in Atherosclerosis Director, Discovery Translation Colorado Clinical & Translational Science Institute University of Colorado Anschutz Medical Campus Director, Lipid Clinic, University Hospital

Suzanne Oparil, MD
Professor of Medicine, Physiology & Biophysics Director, Vascular Biology & Hypertension Program Division of Cardiovascular Disease Department of Medicine University of Alabama at Birmingham

Jorge Plutzky, MD
Associate Professor of Medicine Harvard Medical School Director, Vascular Disease Prevention Program Brigham and Women’s Hospital

Paul Ridker, MD, MPH
Clinical Associate for Cardiovascular Disease Prevention Brigham and Women’s Hospital Eugene Braunwald Professor of Medicine Harvard Medical School

Lewis Rubin, MD
Emeritus Professor of Medicine University of California, San Diego

Marc Sabatine, MD, MPH
Chairman, TIMI Study Group Associate Physician, Cardiovascular Medicine Brigham and Women’s Hospital Associate Professor of Medicine Harvard Medical School

Arya Sharma, MD, PhD
Professor of Medicine Chair, Obesity Research and Management University of Alberta Clinical Co-Chair Alberta Health Services Obesity Program

Gregg Stone, MD
Professor of Medicine, Columbia University Director, Cardiovascular Research and Education Center for Interventional Vascular Therapy NY-Presbyterian Hosp., Columbia Univ. Medical Ctr. Co-Director, Medical Research and Education The Cardiovascular Research Foundation

Peter Toth, MD, PhD
Director of Preventive Cardiology CGH Medical Center Professor, Clinical Family & Community Medicine University of Illinois College of Medicine

Alan Weder, MD
Professor, Division of Cardiovascular Medicine Department of Internal Medicine Vascular Medicine Program University of Michigan

Carol Wysham, MD
Clinical Assistant Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes and Endocrinology

Jay S. Skyler, MD, MACP
Professor of Medicine, Pediatrics, and Psychology Division of Endocrinology, Diabetes and Metabolism University of Miami Miller School of Medicine Deputy Director for Clinical and Academic Programs Diabetes Research Institute

Myung Park, MD
Associate Professor of Medicine University of Maryland Heart Center Director, Pulmonary Vascular Diseases Program

Richard Pratley, MD
Director, Florida Hospital Diabetes Institute Senior Scientist, Translational Research Institute for Metabolism and Diabetes Professor, Sanford Burnham Medical Research Inst.

Matthew Roe, MD
Associate Professor Duke University School of Medicine Division of Cardiology Duke University Medical Center Duke Clinical Research Institute

Francesco Rubino, MD
Chief, Gastrointestinal Metabolic Surgery Associate Professor of Surgery Director, Metabolic & Diabetes Surgery Center New York-Presbyterian Hospital Weill Cornell Medical Center

Ernst Schaefer, MD
Professor of Medicine Tufts University School of Medicine Senior Scientist and Director Lipid Metabolism Laboratory Jean Mayer USDA HNRCA at Tufts University

Domenic Sica, MD
Professor, Internal Medicine, Nephrology Section Head Clinical Pharmacology & Hypertension Virginia Commonwealth University

Neil Stone, MD, MACP
Bonner Professor of Preventive Cardiology Feinberg School of Medicine, Northwestern Univ. Medical Director, Vascular Center Bluhm Cardiovascular Institute Northwestern Memorial Hospital

Sotirios Tsimikas, MD
Professor of Medicine Director, Vascular Medicine Division of Cardiovascular Diseases University of California San Diego School of Medicine

William White, MD
Professor and Chief, Division of Hypertension & Clinical Pharmacology Pat and Jim Calhoun Cardiovascular Center Medical Director, Clinical Trials Unit University of Connecticut School of Medicine

Bernard Zinman, MD
Director, Bluhm Cardiovascular Institute Medical Director, Vascular Center University of Toronto

“Integrated management of all aspects of cardiometabolic risk – from lifestyle modifications to supplements to prescription drugs – is the only way to approach this 21st-century epidemic. The CMHC brings it all together with experts from multiple disciplines – providing the state of the art on this rapidly advancing area.”

– Daniel Rader, MD
Agenda

Wednesday, October 10, 2012

12:45 – 2:15pm  Afternoon Symposium
2:30 – 3:45pm  Symposium
4:00 – 5:15pm  Symposium
6:30 – 8:30pm  Dinner Symposia

“With the rising tide of the ‘epidemic’ in diabetes and obesity, we all need to monitor closely what is new to prevent an avalanche of cardiovascular disease. The Cardiometabolic Health Congress is the best way to stay on top of this increasingly important and critical field.” – Christopher Cannon, MD

Thursday, October 11, 2012

6:15 – 7:45am  Breakfast Symposia
8:00 – 8:05am  Opening Remarks
Jay Skyler, MD
8:05 – 9:15am  Keynote Session
Cardiometabolic Health 2012: Guideline Updates & Implications for Clinical Practice
moderator: Robert Eckel, MD
presenters: Silvio Inzucchi, MD; Suzanne Oparil, MD; Neil Stone, MD
9:15 – 9:45am  Prevention of CVD in Patients with Diabetes
James Gavin III, MD
9:45 – 10:15am  Glycemic Control During and After CCU/Inpatient Setting
Irl Hirsch, MD
10:15 – 11:15am  Morning Break/Exhibit Hall
11:15am – 12:00pm  T2DM 2012: Expert Recommendations & Evidence-Based Strategies for Achieving Optimal Results
moderator: Jay Skyler, MD
panelists: James Gavin III, MD; Irl Hirsch, MD; Silvio Inzucchi, MD
12:15 – 1:45pm  Lunch Symposia

2:00 – 2:45pm  Keynote Session
Are We Ready for Bariatric Surgery as the Treatment of Choice for T2DM?
Francesco Rubino, MD
2:45 – 3:15pm  Expanding Evidence that Obesity Can Be Successfully Managed by Behavioral Interventions
Lawrence Appel, MD
3:15 – 4:15pm  The Mechanistic and Therapeutic Link Between Obesity and Diabetes: Where Are We & Where Do We Need to Go?
Allison Goldfine, MD
4:15 – 4:45pm  Afternoon Break/Exhibit Hall
4:45 – 5:30pm  Integrating Evidence-Based Strategies into Clinical Practice for the Management of Patients with Obesity & T2DM
moderator: Robert Eckel, MD
panelists: Lawrence Appel, MD; James Gavin III, MD; Allison Goldfine, MD; Irl Hirsch, MD; Silvio Inzucchi, MD; Francesco Rubino, MD
5:30pm  Closing Remarks
Robert Eckel, MD
5:45 – 6:45pm  Welcome Reception
7:00 – 9:00pm  Dinner Symposium

“Cardiometabolic risk is at the core of our efforts at preventing morbidity and mortality for our patients with type 2 diabetes. Addressing these challenges through a clear, effective and practical approach is at the core of this program.”
– Luigi Meneghini, MD

Agenda and faculty are subject to change.
Friday, October 12, 2012

6:15 – 7:45am  Breakfast Symposium
8:05 – 8:10am  Opening Remarks
Christie Ballantyne, MD

8:10 – 9:30am  Keynote Session
Inflammation & Cardiometabolic Risk: Translating the Science into Clinical Practice
 moderator: Christie Ballantyne, MD
presenters: Peter Libby, MD; Paul Ridker, MD

9:30 – 10:30am  Morning Break/Exhibit Hall

10:30 – 11:45am  Late-Breaking Clinical Trials & FDA Update: How Will the Latest Data Impact Clinical Practice?
 moderator: Robert Eckel, MD
panelists: Christie Ballantyne, MD; Keith Ferdinand, MD; Jay Skyler, MD; Stephen Wiviott, MD

12:00 – 1:30pm  Lunch Symposia

1:45 – 3:15pm  Clinical Controversies in Lipid Management: Viewpoints of Guidelines & Case-Based Discussion
 moderator: Christie Ballantyne, MD
panelists: Harold Bays, MD; Robert Eckel, MD; JoAnne Foody, MD

3:15 – 4:15pm  Afternoon Break/Exhibit Hall

6:00 – 8:00pm  Dinner Symposium

“As clinicians, we face many challenges in caring for the ever-increasing number of patients with cardiometabolic risk. CMHC provides an invaluable opportunity to hear cutting-edge science, clinical perspectives and the newest information on managing CM risk.”  – JoAnne Foody, MD

Saturday, October 13, 2012

6:15 – 7:45am  Breakfast Symposium
8:05 – 8:10am  Opening Remarks
Christie Ballantyne, MD

8:10 – 9:15am  Hot Topics in Thrombosis & ACS
 moderator: Deepak L. Bhatt, MD
panelists: Peter Berger, MD; Matthew Roe, MD

9:15 – 9:45am  Comparative Approach to Achieving BP Goals: How Many Ways to Interpret the Data?
 George Bakris, MD

9:45 – 10:00am  Morning Break

10:00am – 12:00pm  Clinical Dilemmas & Evidence-Based Solutions for HTN Management
 moderator: George Bakris, MD
panelists: Domenic Sica, MD; Alan Weder, MD; William White, MD

12:00pm  Closing Remarks
George Bakris, MD

“One of the major strengths of this program is the faculty’s incredible breadth and depth of knowledge about cardiometabolic risk. I rarely learn so much from a conference where I am also a speaker. I may be biased, but I think this is a conference well worth attending.”  – Anne Peters, MD

Agenda and faculty are subject to change.

“The importance of diabetes as a risk factor for cardiovascular disease continues to grow. The CMHC nicely brings together all the different perspectives that are necessary to provide optimal care to reduce cardiovascular risk.”  – Deepak L. Bhatt, MD
Corporate-Supported & Sponsored Symposia

Wednesday, October 10, 2012

12:45pm – 2:15pm
Afternoon Symposium
PAH Management 2012: Expert Analysis of Landmark Trials, Long-Term Outcomes & Implications for Clinical Practice
Harrison Farber, MD; Myung Park, MD; Lewis Rubin, MD
Supported by an educational grant from Actelion Pharmaceuticals US, Inc.

2:30 – 3:45pm
Symposium (non-CME)
Fixed-Dose Triple Combination Therapy for Patients with Uncontrolled Hypertension on Dual Combination Therapy
Robert Busch, MD, FACE
Sponsored by Daiichi Sankyo, Inc.

4:00 – 5:15pm
Symposium (non-CME)
Vascepa: A New Therapy for the Treatment of Severe Hypertriglyceridemia
Harold Bays, MD
Sponsored by Amarin Pharma Inc.

6:30 – 8:30pm
Dinner Symposium A
Personalized T2DM Management: Maximizing the Role of GLP-1 RA Therapy in the Continuum of Care
Richard Bergenstal, MD; Robert Chilton, DO; Anne Peters, MD; Carol Wysham, MD
Supported by an educational grant from Amylin Pharmaceuticals, Inc.

6:30 – 8:00pm
Dinner Symposium B (non-CME)
New Treatment Options for Obesity
Donna Ryan, MD
Sponsored by VIVUS, Inc.

Thursday, October 11, 2012

6:15 – 7:45am
Breakfast Symposium A
Intensive Glycemic Control & CV Risk Reduction: The Impact of Early Insulin Therapy on Macrovascular Outcomes in Patients with Dysglycemia
Richard Bergenstal, MD; Vivian Fonseca, MD; Jorge Plutzky, MD; Matthew Riddle, MD
Supported by an educational grant from Sanofi-aventis U.S. Inc., A SANOFI COMPANY

6:15 – 7:45am
Breakfast Symposium B
Obesity Management 2012: Novel Targeting of the CNS for Weight Loss, Glycemic Control & Cardiovascular Risk Reduction
Caroline Apovian, MD; Harold Bays, MD; Robert Eckel, MD; Robert Kushner, MD
Supported by an educational grant from Eisai Inc.

12:15 – 1:45pm
Lunch Symposium A
Basal Insulin 2012: A New Generation of Strategies to Optimize Glucose Control
Timothy Bailey, MD; Irl Hirsch, MD; Luigi Meneghini, MD; Bernard Zinman, MD
Supported by an educational grant from Novo Nordisk, Inc.

6:30 – 8:00pm
Dinner Symposium
GLP-1 Agonist Therapy 2012: Cutting-Edge Data and Clinical Implications for the Spectrum of Patients with T2DM
Vivian Fonseca, MD; Richard Pratley, MD; Julio Rosenstock, MD; Bernard Zinman, MD
Supported by an educational grant from Kowa Pharmaceuticals America, Inc. and Lilly USA, LLC

7:00 – 9:00pm
Dinner Symposium A
Personalized T2DM Management: Maximizing the Role of GLP-1 RA Therapy in the Continuum of Care
Richard Bergenstal, MD; Robert Chilton, DO; Anne Peters, MD; Carol Wysham, MD
Supported by an educational grant from Amylin Pharmaceuticals, Inc.

7:00 – 9:00pm
Dinner Symposium B (non-CME)
New Treatment Options for Obesity
Donna Ryan, MD
Sponsored by VIVUS, Inc.

“The CMHC has rapidly become the most illuminating annual forum for updates on the mechanisms underlying the global scourge confronting populations worldwide, and the scientific basis of rational prevention and treatment paradigms.”  – Om Ganda, MD

Agenda and faculty are subject to change.
Corporate-Supported & Sponsored Symposia

Friday, October 12, 2012

6:15 – 7:45am
Breakfast Symposium A
A Closer Look at Severe and Familial Hypercholesterolemia: Expert Analysis of Pathophysiology and the Role of ApoB Inhibition
Sergio Fazio, MD; Allan Sniderman, MD; Sotirios Tsimikas, MD; James A. Underberg, MD
Supported by an educational grant from Genzyme, A SANOFI COMPANY

6:15 – 7:45am
Breakfast Symposium B
Glycemic Control & CV Outcomes in Perspective: Expert Analysis of Clinical Trials Evaluating Oral & Incretin-based Therapies
Deepak L. Bhatt, MD; Jaime Davidson, MD; Jorge Plutzky, MD; Benjamin Scirica, MD
Supported by an educational grant from Bristol-Myers Squibb and AstraZeneca LP

6:00 – 8:00pm
Dinner Symposium
Harold Bays, MD; Deepak L. Bhatt, MD; William Cromwell, MD; Terry Jacobson, MD; Ernst Schaefer, MD
Supported by an educational grant from Amarin Pharma Inc.

12:00 – 1:30pm
Lunch Symposium A
Expert Analysis of Innovative Antiplatelet Data: Clinical Implications for Patients with ACS Undergoing PCI
Michelle O’Donoghue, MD; Marc Sabatine, MD; Gregg Stone, MD; Stephen Wiviott, MD
Supported by an educational grant from Daiichi Sankyo, Inc. and Eli Lilly and Company

12:00 – 1:30pm
Lunch Symposium B
Advances in Weight-Loss Management: Examining the Clinical Impact of Novel Therapies on Obesity, Diabetes & Cardiometabolic Risk
Robert Eckel, MD; W. Timothy Garvey, MD; Lee M. Kaplan, MD; Jorge Plutzky, MD; Arya Sharma, MD
Supported by an educational grant from VIVUS, Inc.

6:15 – 7:45am
Breakfast Symposium A
A Closer Look at Severe and Familial Hypercholesterolemia: Expert Analysis of Pathophysiology and the Role of ApoB Inhibition
Sergio Fazio, MD; Allan Sniderman, MD; Sotirios Tsimikas, MD; James A. Underberg, MD
Supported by an educational grant from Genzyme, A SANOFI COMPANY

6:15 – 7:45am
Breakfast Symposium B
Glycemic Control & CV Outcomes in Perspective: Expert Analysis of Clinical Trials Evaluating Oral & Incretin-based Therapies
Deepak L. Bhatt, MD; Jaime Davidson, MD; Jorge Plutzky, MD; Benjamin Scirica, MD
Supported by an educational grant from Bristol-Myers Squibb and AstraZeneca LP

12:00 – 1:30pm
Lunch Symposium A
Expert Analysis of Innovative Antiplatelet Data: Clinical Implications for Patients with ACS Undergoing PCI
Michelle O’Donoghue, MD; Marc Sabatine, MD; Gregg Stone, MD; Stephen Wiviott, MD
Supported by an educational grant from Daiichi Sankyo, Inc. and Eli Lilly and Company

12:00 – 1:30pm
Lunch Symposium B
Advances in Weight-Loss Management: Examining the Clinical Impact of Novel Therapies on Obesity, Diabetes & Cardiometabolic Risk
Robert Eckel, MD; W. Timothy Garvey, MD; Lee M. Kaplan, MD; Jorge Plutzky, MD; Arya Sharma, MD
Supported by an educational grant from VIVUS, Inc.

6:00 – 8:00pm
Dinner Symposium
Harold Bays, MD; Deepak L. Bhatt, MD; William Cromwell, MD; Terry Jacobson, MD; Ernst Schaefer, MD
Supported by an educational grant from Amarin Pharma Inc.

Saturday, October 13, 2012

6:15 – 7:45am
Breakfast Symposium
Expert Perspectives on Endothelial Function, HTN, and CV Risk: Cutting-Edge Data on the Impact of Novel Beta Blockers along the HTN Continuum of Care
George Bakris, MD; Keith Ferdinand, MD; Thomas Giles, MD; Addison Taylor, MD
Supported by an educational grant from Forest Laboratories, Inc.

6:15 – 7:45am
Breakfast Symposium
Expert Perspectives on Endothelial Function, HTN, and CV Risk: Cutting-Edge Data on the Impact of Novel Beta Blockers along the HTN Continuum of Care
George Bakris, MD; Keith Ferdinand, MD; Thomas Giles, MD; Addison Taylor, MD
Supported by an educational grant from Forest Laboratories, Inc.

Agenda and faculty are subject to change.

Only 2012 CMHC participants may register for corporate-supported & sponsored symposia. Seating is limited and available on a first-come, first-serve basis.
For symposia updates and additions, please visit www.cardiometabolichealth.org/agenda.asp

“Cardiometabolic health, including the control of associated cardiovascular risk factors, is a prominent challenge globally to medicine now and in the future. Furthermore, it is essential to better define which patients are at greatest risk for cardiovascular morbidity and mortality, and how best to curtail that risk.”
– Keith Ferdinand, MD
Program Overview

Statement of Need*

The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care professionals in the United States. The prevalence of most cardiometabolic risk factors – especially hypertension, diabetes, and obesity – continues to rise. In the years ahead, American physicians should expect to treat unprecedented numbers of patients at high risk for morbidity and mortality from cardiovascular disease. In 2000, approximately 32% of U.S. adults had the metabolic syndrome, a constellation of cardiometabolic risk factors including excessive abdominal fat, insulin resistance, dyslipidemia, and hypertension. Today, that figure has climbed to 34% and may even be as high as 38%, depending on the criteria used to define the syndrome.

Cardiometabolic Risk Factors Are Undertreated and Difficult to Manage

Despite the well-documented risks of unchecked diabetes, obesity, hypertension, and dyslipidemia, these conditions are commonly undertreated. Even when treated, they remain stubbornly difficult to manage.

- Half or more of treated patients with diabetes fail to meet recommended target HbA1c goals. Analyses of data from National Health and Nutrition Examination surveys found that only one-half to one-third of treated patients achieve the American Diabetes Association’s recommended HbA1c target of 7% or less. In addition, a report released by the American Association of Clinical Endocrinologists stated that two out of three patients with type 2 diabetes were not achieving the Association’s recommended HbA1c goal of 6.5% or less.
- When it comes to first-line therapy for obesity – diet and exercise – few patients succeed, and any improvements are usually modest. Current pharmacotherapy options are limited. Available obesity drugs have, to date, produced only modest weight loss in most patients and have been linked to adverse gastrointestinal effects and mood disorders. Furthermore, many clinicians do not address diet and exercise for weight loss with their patients, citing a lack of belief that lifestyle changes can work, lack of understanding of how to counsel patients about lifestyle change, and inadequate amounts of time and personnel.
- Only 71% of patients with hypertension are receiving any form of treatment. Of these, less than half (48%) have their blood pressure under control; hypertension remains uncontrolled in 52% of treated patients.
- Less than half of those who qualify for any kind of lipid-modifying treatment to reduce their risk of coronary heart disease are receiving it. In fact, less than half of even the highest-risk individuals – those with symptomatic coronary heart disease – are receiving lipid-lowering treatment. Of those being treated, only about one-third are achieving target goals.

Conclusion

Healthcare professionals play a major role in stemming the future burden of cardiovascular disease, diabetes, and associated comorbidities by employing aggressive strategies for the early identification and comprehensive management of patients presenting with multiple cardiometabolic risk factors. The 2012 Cardiometabolic Health Congress will translate the latest cutting-edge medical research into practical, clinical approaches for preventing, delaying, and managing cardiovascular and metabolic risk. The goal is to provide the medical community with evidence-based interventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.

Purpose Statement

The goal of the Congress is to improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.

* To access the 2012 CMHC full statement of need and reference list, please visit www.cardiometabolichealth.org/2012/accreditation.asp.

Target Audience & Learning Objectives

The CMHC is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk.

At the end of the Congress, participants will be able to:

- Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities.
- Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.
- Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for particular patients based on their risk profiles.
- Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mortality from cardiovascular and metabolic disease.

Purpose Statement

The goal of the Congress is to improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.

* To access the 2012 CMHC full statement of need and reference list, please visit www.cardiometabolichealth.org/2012/accreditation.asp.

Save the DATE!

The CMHC presents...

Cardiometabolic Week™

October 2 – 5, 2013 • Boston, MA
Accreditation Information

Earn 29.25 CME Credits

Physician Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources and HealthScience Media, Inc. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this live activity for a maximum of 29.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP – American Academy of Family Physicians
This Live activity, 2012 Cardiometabolic Health Congress, with a beginning date of 10/10/12, has been reviewed and is acceptable for up to 28.5 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Nurse Practitioners
This program is approved for 28.5 contact hours of continuing education (which includes 20.5 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1207258.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Nursing Accreditation
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 29.25 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 29.25 contact hours.

Registered Dietitian Accreditation
Medical Education Resources (Provider Number ME110) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 29.25 continuing professional education units (CPEUs) for completion of this program/material.

Pharmacy Accreditation
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 29.25 contact hour(s) (2.925 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Program Number - 0816-9999-12-005-L01-P)
There is a registration fee for this educational activity.
This activity is certified as Knowledge based CPE.

Attention Certified Diabetes Educators: The 2012 Cardiometabolic Health Congress (CMHC) is accredited by Medical Education Resources (MER). MER is accredited by the ACCME, ANCC, ACPE, and the CDR to provide continuing medical education credits. All of these accredited organizations are recognized by the AADE when applying for CDE renewal of certification or for initial certification.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Supporters & Sponsors

**Association Supporters**
Current Members of Our Association Supporters Receive a $100 Discount!

![Supporters & Sponsors Logos](image)

**Publication Supporters**

![Publication Supporters Logos](image)
Supporters & Sponsors

The 2012 CMHC gratefully acknowledges the educational grant support and sponsorship provided by the following organizations.

Platinum Supporters

- AMARIN
- VIVUS
- Novo Nordisk

Gold Supporters

- Kowa
- Lilly
- AstraZeneca
- Bristol-Myers Squibb
- Eisai
- Lilly
- Genzyme
- A SANOFI COMPANY
- Forest Laboratories, Inc.
- SANOFI DIABETES

Gold Sponsors

- AMARIN
- VIVUS

Silver Supporters

- Actelion
- Boehringer Ingelheim
- Lilly

Bronze Supporters

- Takeda
- Sanofi
- Aegerion Pharmaceuticals

Bronze Sponsors

- Genentech
- AstraZeneca

Educational Supporters

- Allergan
2012 Exhibitors & Travel Information

2012 Exhibitors (as of 8/22/12)

- Aegerion Pharmaceuticals
- Akrimax Pharmaceuticals
- Amarin Pharma Inc.
- Athera Biotechnologies
- Atherotech
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Boston Heart Diagnostics
- Daiichi Sankyo
diaDexus
- Eisai
EndoPAT/Itamar Medical Inc.
- Endurance Products Co.
- Ethicon Endo-Surgery
- Everidis Health Sciences
- Forest Pharmaceuticals, Inc.
- Genzyme, A SANOFI COMPANY
- Gilead Sciences, Inc.
- Health Diagnostic Laboratory, Inc.
- Kaneka
- Kowa Pharmaceuticals America, Inc./Lilly USA, LLC
- LipoScience
- Merck & Co., Inc.
- Metabolon
- Metagenics
- Novo Nordisk, Inc.
- Pivotal Therapeutics
- PreDx Diabetes Risk Score
- Pure Encapsulations
- sanofi
- sanofi diabetes
- Santarus, Inc.
- Singulex, Inc.
- SleepImage
- Synageva BioPharma
- VIVUS, Inc.
- XYMOCEN

Hotel & Travel Information

Westin Boston Waterfront Hotel
425 Summer Street
Boston, MA 02210
(617) 532-4600
www.westin.com/boston

The Westin Boston Waterfront Hotel is located in Boston’s artfully revitalized waterfront district and is less than three miles from Logan International Airport.

To book your hotel room, please contact the hotel directly. Mention that you are attending the 2012 Cardiometabolic Health Congress to receive our special negotiated room rate.

The 2012 Cardiometabolic Health Congress discounted room rate is available only until October 3, 2012, on a first-come, first-served basis. Rooms are limited and subject to availability.

For instructions on how to book your hotel accommodations online, visit www.cardiometabolichealth.org/2012/travel.asp

Sponsorship Opportunities

Don’t Miss this Unprecedented Opportunity to Reach 1500 U.S.-Based Practicing Clinicians!

Becoming a sponsor of the 2012 CMHC will provide your company valuable exposure to endocrinologists, cardiologists, and primary care physicians who are on the front line – managing patients with multiple cardiometabolic risk factors.

Sponsorship and exhibit opportunities are offered on a first-come, first-served basis. For more information please contact us at 877.571.4700
info@cardiometabolichealth.org

Complimentary Online CME

The CMHC offers complimentary online CME activities featuring multimedia presentations.

Visit www.cmhc-online.com to get started.

"The CMHC is remarkable for its broad range of topics pertinent to cardiometabolic diseases. This meeting is an excellent opportunity for busy professionals to get a comprehensive update from leaders in the field."

– Richard Pratley, MD
Register by 9/14/2012 and Save Up To $300!

Registration Form

4 Easy Ways to Register

Online: www.cardiometabolichealth.org
Phone: Brittany at 877.571.4700 732.758.0030 - outside the USA
Fax: 866.218.9168
Mail Registration Form with Payment: 2012 Cardiometabolic Health Congress c/o Health Science Media, Inc. 788 Shrewsbury Avenue, Suite 102 Tinton Falls, NJ 07724

Registration Fees

<table>
<thead>
<tr>
<th></th>
<th>Early Bird Discount</th>
<th>Register by 10/8/2012</th>
<th>Onsite Registration After 10/8/2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians*</td>
<td>$695</td>
<td>$795</td>
<td>$895</td>
</tr>
<tr>
<td>Allied Health Professionals*</td>
<td>$595</td>
<td>$695</td>
<td>$795</td>
</tr>
<tr>
<td>Residents/Fellows**</td>
<td>$250</td>
<td>$300</td>
<td>$350</td>
</tr>
<tr>
<td>Industry</td>
<td>$1095</td>
<td>$1295</td>
<td>$1395</td>
</tr>
</tbody>
</table>

* Must be engaged in clinical practice to receive discounted rate.
** ID card from school, residency, or fellowship program is required for verification. No other discounts apply.

Prefix  First Name   Last Name    Degree(s)

Title

Affiliation

Address 1

Address 2

City       State   Zip Code

Tel        Fax

Email

Please indicate your specialty (check one):

☐ Cardiology ☐ Endocrinology ☐ Internal Medicine ☐ Nephrology ☐ Primary Care ☐ Industry ☐ Other ________________

Which best describes your primary workplace setting? (check one):

☐ Office-based ☐ Hospital ☐ Academic ☐ Government ☐ Pharmacy ☐ Industry

Current members of our Association Supporters receive a $100 discount off the registration price.

Indicate which association you are a member of below:


Total Amount Due ________________

Method of Payment ☐ Check ☐ Visa ☐ MasterCard ☐ American Express ☐ Discover

Account Number ________________________ Expiration Date ________________________

Cardholder Name ________________________ Cardholder Signature ________________________

Cancellation Policy

Cancellations must be made in writing via fax to 866.218.9168 or email to info@cardiometabolichealth.org. Refunds, less a $100 service fee, will be given if written cancellation is received no later than September 7, 2012. No refunds will be given after September 7, 2012. To send a substitute, please call 877.571.4700 or email your request to info@cardiometabolichealth.org.
Earn up to 29.25 CME Credits!

Customize Your CMHC Learning Experience
Choose from 15 sessions and 16 complimentary symposia

"The CMHC is the nation’s leading meeting advancing knowledge on cardiometabolic health." – Peter McCullough, MD

"The firestorm of diabetes and metabolic syndrome continues to spread with the increasing incidence of hypertension and hypercholesterolemia acting like gasoline to further fuel the flames and contribute to higher CV morbidity and mortality. The CMHC is the place to get the latest information on quelling this epidemic." – George Bakris, MD

"CMHC brings together a unique assemblage of basic, translational, and clinical experts with a diverse and attentive audience to address an urgent contemporary health challenge that demands such a multidisciplinary approach." – Peter Libby, MD

"It is striking that the CMHC has become the undisputed leader in conferences that address the most important metabolic derangements of our time, due largely to the strength of the faculty and their interactions with an engaged audience." – James Gavin III, MD

Join 64 expert faculty, 1500 colleagues & 33 medical associations to combat the global health crisis emanating from cardiovascular & metabolic disease.

www.cardiometabolichealth.org

This activity is jointly sponsored by HealthScience Media, Inc. (HSM), and Medical Education Resources, Inc. (MER).